Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma

NCT03697655 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

274

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab 20 MG/ML [Darzalex]

Sponsor

Polish Myeloma Consortium

Collaborators

[object Object]
[object Object]